Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Botulinum neurotoxin type A-DP** is a specific pharmaceutical preparation of botulinum neurotoxin type A, a potent neurotoxic protein derived from the bacterium *Clostridium botulinum*. Its principal mechanism of action is the inhibition of acetylcholine release from peripheral cholinergic nerve terminals, which is achieved by internalization of the toxin into nerve cells and subsequent cleavage of the SNARE protein SNAP-25. This block leads to targeted, reversible paralysis of muscles or glands at the injection site. Clinically, botulinum neurotoxin type A products—including type A-DP formulations—are used to treat a range of neuromuscular disorders characterized by involuntary muscle activity (such as dystonias, spasticity, and hemifacial spasm), autonomic dysfunction (such as hyperhidrosis and sialorrhea), as well as for chronic migraine prevention and cosmetic indications for reduction of facial wrinkles[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on botulinum neurotoxin type A-DP.